ELVN - CIK 0001672619
The table below shows Enliven Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | -$19.13M | -$37.40M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$173.84M | -$36.00M | -$148.41M | -$612.00K | -$191.00K | -$16.72M |
| Dividends paid | - | - | - | - | - |
Enliven Therapeutics, Inc. reported operating cash flow of -$70.30M for fiscal year 2025. That is up 3.9% from -$73.19M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$21.88M (FY 2019) to -$70.30M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $218.87M | $133.16M | $234.29M | -$1.80M | -$1.02M | $96.88M |